The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects, good and/or bad, Erlotinib
has on Myelodysplastic syndrome. Myelodysplastic syndrome is a group of blood diseases where
the bone marrow (spongy space in long bones which is the factory for blood cell production)
does not make enough blood cells and therefore there is a lack of healthy blood cells in the
body. This can result in anemia, risk for infection and/or bleeding..